{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:55Z","timestamp":1790959375131,"version":"4.1.0"},"reference-count":121,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Ulcerative colitis (UC) is an inflammatory bowel disease in which one-quarter of patients are at risk of developing a severe form of the disease known as acute severe UC (ASUC). This condition exposes patients to serious complications, including toxic megacolon, surgical intervention, and even death. The current therapeutic strategy relies on time-dependent, multi-step algorithms that integrate systemic corticosteroids, calcineurin inhibitors, and biologic agents (specifically infliximab) as medical therapy aimed at avoiding colectomy. Despite this approach, a significant proportion of patients fail to respond to either corticosteroids or infliximab and may require alternative therapeutic options if there is no urgent surgical necessity. These alternatives include other biologics or emerging small molecules, although the evidence supporting these treatments remains extremely low, even considering their well-documented and promising efficacy and safety in moderate-to-severe UC. Conversely, it is necessary to investigate whether infliximab can be effectively replaced or surpassed by other approved biological agents and small molecules as first-line therapy after steroid resistance. This review aims to summarise the available evidence on small molecules, specifically Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators.<\/jats:p>","DOI":"10.3390\/ph18030308","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:46:57Z","timestamp":1740383217000},"page":"308","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-230X","authenticated-orcid":false,"given":"Raffaele","family":"Pellegrino","sequence":"first","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Imperio","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"De Costanzo","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Izzo","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Landa","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assunta","family":"Tambaro","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-0115","authenticated-orcid":false,"given":"Antonietta Gerarda","family":"Gravina","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Federico","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of Inflammatory Bowel Diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO Guidelines on Inflammatory Bowel Disease and Malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and Pathogenesis of Ulcerative Colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global Hospitalization Trends for Crohn\u2019s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses","volume":"21","author":"Buie","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cgh.2016.01.015","article-title":"Mucosal Healing Is Associated With Improved Long-Term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"14","author":"Shah","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cca.2020.08.025","article-title":"Calprotectin in Inflammatory Bowel Disease","volume":"510","author":"Qujeq","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The Pattern and Outcome of Acute Severe Colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J. Crohns Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/gutjnl-2024-332489","article-title":"Acute Severe Ulcerative Colitis Trials: The Past, the Present and the Future","volume":"73","author":"Honap","year":"2024","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology Consensus Guidelines on the Management of Inflammatory Bowel Disease in Adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Marsal, J., Barreiro-de Acosta, M., Blumenstein, I., Cappello, M., Bazin, T., and Sebastian, S. (2022). Management of Non-Response and Loss of Response to Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front. Med., 9.","DOI":"10.3389\/fmed.2022.897936"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-Analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.14309\/ajg.0000000000002263","article-title":"Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis","volume":"118","author":"Ahuja","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking Through the Therapeutic Ceiling: What Will It Take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pillay, L., Selvarajah, J., Andrew, B., Christensen, B., Macrae, F., and Segal, J.P. (2024). Future of Acute Severe Ulcerative Colitis-A Narrative Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13247723"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.15592","article-title":"Systematic Review with Meta-Analysis: Mortality in Acute Severe Ulcerative Colitis","volume":"51","author":"Dong","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e001587","DOI":"10.1136\/bmjgast-2024-001587","article-title":"Predictors for Colectomy in Patients with Acute Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"11","author":"Zheng","year":"2024","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.7869\/tg.177","article-title":"Factors Precipitating Acute Ulcerative Colitis","volume":"35","author":"Puri","year":"2014","journal-title":"Trop. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ecco-jcc\/jjaa036","article-title":"Ulcerative Colitis and Cytomegalovirus Infection: From A to Z","volume":"14","author":"Mourad","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00042737-200104000-00026","article-title":"Heparin Therapy for Ulcerative Colitis? Effects and Mechanisms","volume":"13","author":"Michell","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Institute Clinical Guidelines Committee AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/ibd\/izy383","article-title":"Systematic Review and Meta-Analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis","volume":"25","author":"Choy","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","article-title":"Ciclosporin versus Infliximab in Patients with Severe Ulcerative Colitis Refractory to Intravenous Steroids: A Parallel, Open-Label Randomised Controlled Trial","volume":"380","author":"Laharie","year":"2012","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus Ciclosporin for Steroid-Resistant Acute Severe Ulcerative Colitis (CONSTRUCT): A Mixed Methods, Open-Label, Pragmatic Randomised Trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gutjnl-2016-313060","article-title":"Long-Term Outcome of Patients with Steroid-Refractory Acute Severe UC Treated with Ciclosporin or Infliximab","volume":"67","author":"Laharie","year":"2018","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1590\/0102-6720201600030017","article-title":"Management of acute severe ulcerative colitis: A clinical update","volume":"29","author":"Sobrado","year":"2016","journal-title":"Arq. Bras. Cir. Dig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00384-012-1602-8","article-title":"Infliximab versus Cyclosporine as Rescue Therapy in Acute Severe Steroid-Refractory Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"28","author":"Chang","year":"2013","journal-title":"Int. J. Color. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1007\/s10620-021-06826-5","article-title":"Rescue Therapy with Intensive Vedolizumab Optimization in a Seventeen-Year-Old Girl with Acute Severe Ulcerative Colitis","volume":"66","author":"Graziano","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/gidisord5030030","article-title":"Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up","volume":"5","author":"Pellegrino","year":"2023","journal-title":"Gastrointest. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.cgh.2018.04.060","article-title":"Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease","volume":"17","author":"Christensen","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/ibd\/izab328","article-title":"A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab","volume":"28","author":"Tarabar","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/apt.15616","article-title":"Efficacy and Safety of Induction Therapy with Calcineurin Inhibitors Followed by Vedolizumab Maintenance in 71 Patients with Severe Steroid-Refractory Ulcerative Colitis","volume":"51","author":"Ollech","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and Safety of Biologics and Small Molecule Drugs for Patients with Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue Therapies for Steroid-Refractory Acute Severe Ulcerative Colitis: A Review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e00604","DOI":"10.14309\/crj.0000000000000604","article-title":"Combining Cyclosporine With Ustekinumab in Acute Severe Ulcerative Colitis","volume":"8","author":"Shaffer","year":"2021","journal-title":"ACG Case Rep. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1756284820954112","DOI":"10.1177\/1756284820954112","article-title":"Successful Cyclosporin and Ustekinumab Combination Therapy in a Patient with Severe Steroid-Refractory Ulcerative Colitis","volume":"13","author":"Ganzleben","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2022.03.008","article-title":"Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis","volume":"21","author":"Veyrard","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_42","first-page":"341","article-title":"Systematic Review and Meta-Analysis of Third-Line Salvage Therapy with Infliximab or Cyclosporine in Severe Ulcerative Colitis","volume":"29","author":"Feuerstein","year":"2016","journal-title":"Ann. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/apt.17938","article-title":"Effectiveness and Safety of a Third-Line Rescue Treatment for Acute Severe Ulcerative Colitis Refractory to Infliximab or Ciclosporin (REASUC Study)","volume":"59","author":"Riestra","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/ibd\/izae020.194","article-title":"Upadacitinib as second- and third-line salvage therapy for refractory acute severe ulcerative colitis","volume":"30","author":"Hassan","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/apt.17973","article-title":"Editorial: Sequencing Rescue Therapy for Acute Severe Ulcerative Colitis-Ready for Revision?","volume":"59","author":"Derikx","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","article-title":"Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease","volume":"40","author":"Brady","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOG.0000000000000849","article-title":"Management of Refractory Inflammatory Bowel Disease","volume":"38","author":"Gergely","year":"2022","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.14309\/ajg.0000000000002676","article-title":"Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study","volume":"119","author":"Dragoni","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.nano.2014.05.013","article-title":"Small Molecule Delivery through Nanofibrous Scaffolds for Musculoskeletal Regenerative Engineering","volume":"10","author":"Carbone","year":"2014","journal-title":"Nanomedicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.tibtech.2010.05.005","article-title":"Mass Spectrometric Imaging of Small Molecules","volume":"28","author":"Svatos","year":"2010","journal-title":"Trends Biotechnol."},{"key":"ref_51","unstructured":"Ganellin, R., Roberts, S., and Jefferis, R. (2013). Chapter 5\u2014Similarities and Differences in the Discovery and Use of Biopharmaceuticals and Small-Molecule Chemotherapeutics. Introduction to Biological and Small Molecule Drug Research and Development, Elsevier."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.dld.2024.07.018","article-title":"Small Molecules for Inflammatory Bowel Disease and the Risk of Infection and Malignancy: A Systematic Review and Meta-Analysis","volume":"56","author":"Chen","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ben Ghezala, I., Charkaoui, M., Michiels, C., Bardou, M., and Luu, M. (2021). Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070637"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and Consequences of Jak-STAT Signaling in the Immune System","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT Pathway Targeting for the Treatment of Inflammatory Bowel Disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The Role of JAK\/STAT Signaling Pathway and Its Inhibitors in Diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II Cytokines, JAKs, and New Strategies for Treating Autoimmune Diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Parmentier, J.M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H.S., Padley, R.J., George, J.S., and Hyland, D. (2018). In Vitro and in Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494). BMC Rheumatol., 2.","DOI":"10.1186\/s41927-018-0031-x"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases","volume":"191","author":"Galien","year":"2013","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, Efficacy and Safety of JAKinibs: New Evidence for a Still Evolving Story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An Overview of Sphingolipid Metabolism: From Synthesis to Breakdown","volume":"688","author":"Gault","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1242\/jcs.02637","article-title":"Sphingosine 1-Phosphate and Ceramide 1-Phosphate: Expanding Roles in Cell Signaling","volume":"118","author":"Chalfant","year":"2005","journal-title":"J. Cell Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte Egress from Thymus and Peripheral Lymphoid Organs Is Dependent on S1P Receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ni1545","article-title":"Finding a Way out: Lymphocyte Egress from Lymphoid Organs","volume":"8","author":"Schwab","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eaar5551","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-Phosphate: Lipid Signaling in Pathology and Therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000362992","article-title":"Sphingosine 1-Phosphate in Blood: Function, Metabolism, and Fate","volume":"34","author":"Thuy","year":"2014","journal-title":"Cell Physiol. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11010-011-1154-1","article-title":"Regulation of Metabolism and Transport of Sphingosine-1-Phosphate in Mammalian Cells","volume":"363","author":"Liu","year":"2012","journal-title":"Mol. Cell Biochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbrc.2007.03.123","article-title":"Lack of Sphingosine 1-Phosphate-Degrading Enzymes in Erythrocytes","volume":"357","author":"Ito","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature24053","article-title":"Mfsd2b Is Essential for the Sphingosine-1-Phosphate Export in Erythrocytes and Platelets","volume":"550","author":"Vu","year":"2017","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1167449","article-title":"The Sphingolipid Transporter Spns2 Functions in Migration of Zebrafish Myocardial Precursors","volume":"323","author":"Kawahara","year":"2009","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.1103187108","article-title":"Endothelium-Protective Sphingosine-1-Phosphate Provided by HDL-Associated Apolipoprotein M","volume":"108","author":"Christoffersen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/intimm\/dxz037","article-title":"Sphingosine 1-Phosphate and Inflammation","volume":"31","author":"Obinata","year":"2019","journal-title":"Int. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Alimentiv Translational Research Consortium (ATRC) Sphingosine 1-Phosphate Modulation and Immune Cell Trafficking in Inflammatory Bowel Disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40265-022-01762-8","article-title":"Ozanimod: A Review in Ulcerative Colitis","volume":"82","author":"Paik","year":"2022","journal-title":"Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: First Approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis","volume":"81","year":"2021","journal-title":"Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/mi.2016.35","article-title":"Sphingosine-1-Phosphate Receptor-1 (S1P1) Is Expressed by Lymphocytes, Dendritic Cells, and Endothelium and Modulated during Inflammatory Bowel Disease","volume":"10","author":"Karuppuchamy","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: Ulcerative Colitis in Adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cgh.2020.03.072","article-title":"Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis","volume":"19","author":"Battat","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s005350050218","article-title":"Mucosal Proinflammatory Cytokine Production Correlates with Endoscopic Activity of Ulcerative Colitis","volume":"34","author":"Ishiguro","year":"1999","journal-title":"J. Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/ecco-jcc\/jjy171","article-title":"ANP32E, a Protein Involved in Steroid-Refractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach","volume":"13","author":"Naves","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2036.2006.03156.x","article-title":"Review Article: Steroid Resistance in Inflammatory Bowel Disease\u2014Mechanisms and Therapeutic Strategies","volume":"25","author":"Creed","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ecco-jcc\/jjab109","article-title":"Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis","volume":"16","author":"Gilmore","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/ecco-jcc\/jjae111","article-title":"Rescue Therapies for Steroid-Refractory Acute Severe Ulcerative Colitis: A Systemic Review and Network Meta-Analysis","volume":"18","author":"Huang","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000514781","article-title":"Tofacitinib: An Option for Acute Severe Ulcerative Colitis?","volume":"29","author":"Santos","year":"2022","journal-title":"GE Port. J. Gastroenterol."},{"key":"ref_94","first-page":"e45416","article-title":"Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis","volume":"15","author":"Malakar","year":"2023","journal-title":"Cureus"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ibd\/izad135","article-title":"Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study","volume":"30","author":"Bacsur","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0140-6736(90)91521-B","article-title":"Preliminary Report: Cyclosporin in Treatment of Severe Active Ulcerative Colitis","volume":"336","author":"Lichtiger","year":"1990","journal-title":"Lancet"},{"key":"ref_98","first-page":"97","article-title":"Successful Initial Tofacitinib Treatment for Acute Severe Ulcerative Colitis with Steroid Resistance: A Case Series","volume":"36","author":"Komeda","year":"2023","journal-title":"Ann. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/ibd\/izab087","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review","volume":"27","author":"Jena","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17474124.2022.2106216","article-title":"Positioning of Tofacitinib in Treatment of Ulcerative Colitis: A Global Perspective","volume":"16","author":"Mishra","year":"2022","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/apt.16482","article-title":"Editorial: Is Tofacitinib Another Rescue Option for Acute Severe Ulcerative Colitis?","volume":"54","author":"Honap","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of Venous and Arterial Thromboembolic Events Reported in the Tofacitinib Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis Development Programmes and from Real-World Data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/ecco-jcc\/jjaa018","article-title":"Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-World Experience","volume":"14","author":"Kotwani","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.dld.2023.05.021","article-title":"The Current Role of Tofacitinib in Acute Severe Ulcerative Colitis in Adult Patients: A Systematic Review","volume":"55","author":"Mpakogiannis","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis","volume":"17","author":"Berinstein","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1007\/s10620-022-07439-2","article-title":"Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series","volume":"67","author":"Xiao","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/imj.16192","article-title":"Outcomes out to 12 Months after Sequential Use of High-Dose Tofacitinib Following Infliximab in Acute Severe Ulcerative Colitis","volume":"53","author":"Eqbal","year":"2023","journal-title":"Intern. Med. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.gastrohep.2023.10.003","article-title":"Colombian Experience with the Use of Tofacitinib in Severe Acute Ulcerative Colitis: A Case Series Study","volume":"47","author":"Cuadros","year":"2024","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_110","first-page":"e71485","article-title":"Utility of Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis","volume":"16","author":"Ranjan","year":"2024","journal-title":"Cureus"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/ibd\/izaa357","article-title":"High-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF","volume":"27","author":"Sedano","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1093\/ibd\/izab181","article-title":"Success of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-Refractory Ulcerative Colitis","volume":"27","author":"Yang","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gastrohep.2021.05.005","article-title":"Tofacitinib for the Treatment of Acute Severe Ulcerative Colitis Refractory to Infliximab","volume":"45","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1097\/PG9.0000000000000241","article-title":"Tofacitinib to Treat Severe Acute Refractory Colitis in a Teenager: Case Report and Review of the Literature","volume":"3","author":"Girard","year":"2022","journal-title":"JPGN Rep."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Gravina, A.G., Pellegrino, R., Esposito, A., Cipullo, M., Romeo, M., Palladino, G., Iodice, P., Federico, A., and Troiani, T. (2024). The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review. Cancers, 16.","DOI":"10.3390\/cancers16030611"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Gravina, A.G., Pellegrino, R., Palladino, G., Imperio, G., Calabrese, F., Pasta, A., Giannini, E.G., Federico, A., and Bodini, G. (2024). Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand. Biomolecules, 14.","DOI":"10.3390\/biom14091164"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10238-024-01468-z","article-title":"Effectiveness and Safety of Upadacitinib in Acute Severe Ulcerative Colitis Patients from Single Chinese IBD Center: A Monocentric Study","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience","volume":"119","author":"Berinstein","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e00832","DOI":"10.14309\/crj.0000000000000832","article-title":"Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis","volume":"9","author":"Cohen","year":"2022","journal-title":"ACG Case Rep. J."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/308\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:40:54Z","timestamp":1760028054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,23]]},"references-count":121,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ph18030308"],"URL":"https:\/\/doi.org\/10.3390\/ph18030308","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,23]]}}}